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published sources. Societal utility scores were obtained from a
standard gamble study conducted in Canadians. Costs (2006
CDN dollars) and outcomes were discounted at 5%. Incremen-
tal cost-effectiveness ratios (ICERs) were estimated relative to
lumiracoxib. Sensitivity analyses were conducted for all input
parameters to identify inﬂuential inputs. RESULTS: Lumiracoxib
was more effective and less costly (i.e. dominated) in all sub-
groups when compared to celecoxib. Compared to celecoxib,
lumiracoxib was predicted to reduce clinical and complicated
events in non-ASA patients by 10 and 55% respectively. ICERs
ranged from −$11,253/QALY to −$187,203/QALY for average
risk patients and became more favorable over the cohort’s life-
time. Results were most sensitive to the utility of arthritis and
adverse event rates but the interpretation was robust. Compared
to the majority of secondary treatment algorithms, lumiracoxib
also had an attractive cost-effectiveness proﬁle. CONCLUSION:
From an economic perspective, lumiracoxib is an attractive treat-
ment choice for Canadian OA patients and is more cost-effec-
tive than celecoxib.
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ECONOMIC EVALUATION OF TUMOR NECROSIS FACTOR
INHIBITORS IN THE TREATMENT OF ANKYLOSING
SPONDYLITIS
Parekh HH, Kamal KM
Duquesne University, Pittsburgh, PA, USA
OBJECTIVES: Ankylosing spondylitis (AS) is a chronic, pro-
gressive inﬂammatory form of arthritis with annual estimated
costs of US $6720 per patient. Given the chronic nature of AS
and the high costs of the newer treatments such as tumor necro-
sis factor (TNF) inhibitors, the goal of this study is to conduct
an incremental cost-effectiveness analysis of TNF inhibitors com-
pared with a standard treatment option in patients with AS.
METHODS: A Markov simulation model (one-year) was used
to evaluate the incremental cost-effectiveness of three treatments
in patients with AS: 1) etanercept; 2) inﬂiximab; and 3) standard
treatment (NSAIDs). The decision model assumed a base-case
population of 40 year-old men and the efﬁcacy and withdrawal
data were based on clinical trials of respective drugs. The effec-
tiveness measure was Assessments in Ankylosing Spondylitis
20% Response data (ASAS 20) and the incremental cost-effec-
tiveness ratio (ICER) was calculated as additional cost per ASAS
20, compared with the next most expensive option. The study
was conducted from a payer’s perspective and the cost of treat-
ment with each agent included medication costs, monitoring
costs, infusion administration costs, and physician visit costs.
One-way sensitivity analyses were conducted to test the robust-
ness of study results. RESULTS: The annual costs for standard
treatment, etanercept, and inﬂiximab were $3000, $12,000 and
$13,000, respectively. The ICER of etanercept compared with
standard treatment was $10,860.96/ASAS 20, while the ICER 
of inﬂiximab compared with standard treatment was
$26,314.59/ASAS 20. One-way sensitivity analyses indicated
that the conclusions were relatively stable to variations in model
assumptions. CONCLUSION: The introduction of TNF
inhibitors has represented a signiﬁcant advance in the available
treatments for patients with AS. Thus, demonstrating the cost-
effectiveness of these new treatments can be a critical factor in
determining the acceptability of these new therapies especially
since these agents may offer improved function and signiﬁcant
downstream economic savings.
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OBJECTIVES: To compare the cost-effectiveness of once-daily
tramadol extended-release (ER) and branded and generic tra-
madol immediate-release (IR) formulations for the treatment of
chronic osteoarthritis pain from a managed care payer perspec-
tive. METHODS: A one-year model was constructed to compare
the cost per percent pain reduction using tramadol formulations
for treating chronic osteoarthritis pain. Prevalence, clinical efﬁ-
cacy, and model assumptions were based on product labels, clin-
ical study reports, and published literature. Overall costs
included: drug costs (Red Book), concomitant drug costs to treat
adverse events (AEs), and resource utilization costs (ofﬁce visits,
emergency room visits, and inpatient hospitalizations). Effec-
tiveness was deﬁned as percent pain reduction, calculated as
mean change from baseline in pain intensity score (ER 35.37%
and IR 29.63%). Based on the literature a 30% pain reduction
is considered clinically meaningful (Farrar 2001). In the cost-
effectiveness analysis, a linear relationship across all costs and
effectiveness ranges was assumed to extrapolate costs per clini-
cally meaningful pain reduced (30%). Univariate sensitivity
analyses were conducted to determine model inputs with the
most inﬂuence on model results. RESULTS: The overall annual
cost of therapy per patient was $8238 (ER), $8120 (branded IR),
and $7561 (generic IR). The annual patient cost for every per-
centage pain reduction was lowest for ER ($232.90) followed by
generic IR ($255.18) and branded IR ($274.04). The incremen-
tal cost-effectiveness ratio (ICER) for ER versus branded IR was
$20.48 and the ICER for ER versus generic IR was $118.00 per
percentage pain reduction. Sensitivity analyses indicated that the
drug cost for ER has the most inﬂuence on the cost-effectiveness
ratio. CONCLUSION: This analysis suggests the drug acquisi-
tion cost of ER may be offset by its clinical effectiveness, result-
ing to be a more cost-effective treatment alternative.
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OBJECTIVES: To evaluate the all-cause health care costs among
patients with PsA, who received anti-TNF treatment.
METHODS: A retrospective study using the PharMetrics data-
base, compiled from managed care plans throughout the United
States from January 2000 through June 2005, was conducted.
Patients continuously enrolled for 6 months pre- and 12 months
post-diagnosis, and having 2 distinct claims of PsA, were
included in the study. A 6-month period prior to the index diag-
nosis date was used to establish anti-TNF and/or MTX treat-
ment, naïve patients, and to identify new PsA patients. Per
patient per month treatment (PPPM) costs was calculated for
patients during their treatment period. The cost of adverse events
could not be identiﬁed separately in this analysis. A multivariate
model was used to adjust for covariates including age, gender,
number of medical visits, Charlson Co-morbidity Index, and pre-
period health care costs. RESULTS: A total of 357 patients with
PsA were included in the analysis. Nearly half of the patients
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were females. The mean age and Charlson Co-morbidity Index
score were higher among patients who received INF compared
to those on ETA. All-cause PPPM costs were higher among
patients who received ETA ($6320) compared to patients who
received INF ($2313). The magnitude of the difference was
greater among patients who received INF alone ($3368) com-
pared to ETA alone ($8257, p < 0.05). Differences in total health
care costs persisted after adjustment for covariates (p = 0.0366).
Similar results were obtained when excluding outlier patients
with high cost (outliers were deﬁned as those patients with values
more than 2 standard deviations above the mean). CONCLU-
SION: This study indicates that INF therapy is associated with
lower all cause health care costs compared to ETA therapy, in
the treatment of patients with PsA. The choice of a biologic treat-
ment on health care costs should be considered when evaluating
treatment strategies.
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OBJECTIVES: To evaluate trends in utilization and cost of phar-
macologic treatments of osteoarthritis (OA). METHODS: A ret-
rospective analysis of OA patients (>18 years of age) in the
PHARMetrics database during 2001 and 2002 was conducted
using an observation period (January 2003–June 2005) divided
into ten quarters. Patients were retained if they had continuous
eligibility, at least two OA diagnoses, OA drug use during the
observation period, no cancer, HIV or organ transplant, and were
not in a nursing home. The percentage of days of drug availabil-
ity, proportion of patients and cost were evaluated by type of pain
treatment and adjunctive therapy (i.e., ulcer medications, hyp-
notics, and antidepressants). Patients’ treatments were assessed
at the ﬁrst quarter and followed through the tenth quarter.
Random coefﬁcient models for utilization and cost outcomes were
evaluated, by treatment, using mixed model analysis of variance.
RESULTS: Eligible patients (N = 9972) were, on average, 55.1
years old (SD 9.7) and 65.6% were female. Common comor-
bidities included endocrine or immunity disorders (71.9%),
hypertension (59.0%), and obesity (17.6%). At the end of 30
months, the percent change in the number of subjects using COX-
2s and NSAIDs indicated a reduction of 76% and 10%, respec-
tively. Individual growth models on utilization and cost for
COX-2 (p < 0.001) conﬁrmed the trend. Among NSAID users,
35% used 2 or more different NSAIDs and 18.1% of these had
an average time between NSAID switches of 90 days or less. Nar-
cotics showed a signiﬁcant increasing trend in percentage of days
use and costs (p < 0.001). CONCLUSION: Trends over 30
months suggest, increasing narcotic use, high discontinuation of
COX-2s, and a high proportion of NSAID patients with switches
within 90 days. No single dominant therapy over time appeared
in this study suggesting there is a potential for new approaches
and reconsiderations for OA treatment.
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NEW AUDIENCE FOR PATIENT-REPORTED OUTCOMES (PRO)
DATA: PATIENTS
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OBJECTIVES: While health care providers ﬁnd PRO data valu-
able for managing patients’ care, they also see a need for more
patient involvement. This research was conducted to gather
input from patients and providers about the value of health out-
comes data for patients in the area of rheumatoid arthritis with
or without psoriasis. METHODS: We conducted follow-up tele-
phone interviews with a sample of 50 individuals (27 physicians,
11 nurses, 12 patients) who participated in one of two programs
associated with rheumatoid arthritis. The programs were
designed to provide patient feedback about experiences with a
given prescription medication to physicians via one-page graph-
ical reports. The semi-structured interviews included questions
regarding providers’ impressions of the feedback and its value
for patients. Patients were asked about the program and the
value of feedback for them. This qualitative analysis summarizes
their responses. RESULTS: Of the 27 physicians interviewed,
56% (n = 15) were dermatologists and 44% (n = 12) rheuma-
tologists. Eleven nurses from dermatology practices and 12
patients with rheumatoid arthritis were interviewed as well. Par-
ticipants were in general agreement that the feedback was useful
for monitoring patients’ responses to treatment, when viewed in
conjunction with clinical observations. Many providers stated
that they could show the feedback to the patient, “in black and
white”, and begin a discussion. Most patients report participat-
ing in the programs because they want their physicians to receive
the feedback. Many patients also expressed an interest in receiv-
ing the feedback themselves to track their progress, indepen-
dently and relative to other patients. A few physicians echoed
this sentiment, stating that through the feedback patients could
feel connected and that may increase involvement in their care.
Providers however, emphasized that the information be provided
in “patient-friendly” terms. CONCLUSION: Based on this
research, a new audience for health outcomes data—delivered in
simple, straightforward terms—is patients themselves.
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OBJECTIVES: Assess impact of high patient out-of-pocket
expenditures (OOP) on adherence and persistence with biolog-
ics for treatment of RA. METHODS: An incidence cohort of RA
patients with pharmacy claims for etanercept or adalimumab
during 2002–2003 was selected from a database of insurance
claims from self-insured employer health plans (N = 2311).
Adherence was deﬁned as the medication possession ratio
(MPR), proportion of the 365 days follow-up covered by days
supplied. Persistence was determined using a survival analysis of
the likelihood of discontinuing therapy. Patient’s OOP was mea-
sured in two ways: 1) patient’s coinsurance and co-payments per
week of therapy, and 2) proportion of the biologic medication’s
cost paid by patient. Multivariate linear regression models of
MPR and proportional hazard models of persistence estimated
the impact of cost, adjusting for insurance type and demographic
and clinical variables. RESULTS: OOP expenditure averaged $8
per week (SD $14, range $0 to $127). Only a very small pro-
portion of patients (3.9%) paid more than $50 per week. The
mean (SD) MPR for all patients was 0.52 (0.31). Adherence sig-
niﬁcantly decreased with increased weekly OOP (Coeff −0.0035,
P < 0.0001) and when patients paid a higher proportion of
therapy costs (Coeff −0.8890, P < 0.0001). This translates into
approximately one week of therapy lost for every $5.50 increase
in weekly OOP. Adherence was lower for younger patients,
women and those with more comorbidities. Patients whose
